source
- Biogen’s experimental Alzheimer’s therapy shows comparable slowing of cognitive decline in mid-stage trial, paving way to Phase 3Biogen reported that its experimental Alzheimer’s drug slowed cognitive decline in a mid-stage study. The trial showed patients experienced a rate of decline similar to that seen with currently app…
- Bipartisan lawmakers demand AI use details from top Medicare Advantage insurers amid care denial concernsSenators Richard Blumenthal and Josh Hawley have written to UnitedHealth, Humana, CVS and other large Medicare Advantage insurers asking for internal records that detail how artificial intelligence…STAT · 1mo agoRegulatoryNegative